This is a significant improvement in survival for women with this disease, which is most often diagnosed at an advanced stage.

In our trial, women who received part of their chemotherapy via an IP route had a median survival time of 16 months longer than women who received only IV chemotherapy.

This is the longest survival reported to date for advanced ovarian cancer.

But now we have firm data showing we should use (it) in most women with advanced ovarian cancer who have had successful surgery to remove the bulk of their tumor.

These findings underscore the need to educate women about their personal risk of cardiovascular disease and educate them that where there is one risk factor present, there are likely more.

Among the women who made larger reductions in saturated and trans fat we saw trends toward reduction in heart disease.